We report a detailed analysis of a B cell defect affecting a patient girl born from first cousin parents, characterized by a severe non-X-linked agammaglobulinemia with a total absence of CD19 ϩ cells in the periphery. In the bone marrow, CD19 expression was also highly impaired, resulting in the absence of both B and preB compartments. By contrast, CD34 
Introduction
B cell development from pluripotent stem cells proceeds through proB, preB, and B cell stages that may be followed by a variety of experimental approaches: ( a ) sequential acquisition and/or loss of a number of cell surface markers (1, 2) , such as, in humans, CD34, CD10, CD19, CD20; ( b ) occurrence of successive Ig gene rearrangements that follow an essentially regulated kinetics, H → → (3); ( c ) follow-up of fully rearranged gene expression and also detection of germ-line transcripts that precede most rearrangement events (4); and ( d ) identification of mutations occurring in genes responsible for a block in B cell differentiation (5) .
Among the earliest cell surface markers of the B lineage, the surrogate light chains ( ⌿ L) are of special interest. They are encoded by the -like gene in humans (6) (7) (8) or the 5 in the mouse (9) , and the VpreB gene (10, 11) . At the proB cell stage, ⌿ L are expressed at the cell surface in the absence of chains (12) (13) (14) . Recently, using "proB specific" anti-VpreB mAbs, we have identified proB cell subpopulations that are CD34 ϩ ⌿ L ϩ and do or do not express CD10 and/or CD19 markers in normal human bone marrow (see reference 22) . Normal preB cells have been identified within the CD19 ϩ population (15) , either as having ⌿ L associated with (6, (14) (15) (16) (17) , or as a CD34 Ϫ
CD19
ϩ fraction that contains intracytoplasmic chains (18) . In addition, Ig ␣ and Ig ␤ , which constitute the signaling elements of the B cell receptor, and are encoded by the mb1 and B29 genes, respectively (19) , were also detected at the cell surface of preB (20, 21) , but not proB cells (22) .
X-linked agammaglobulinemia (XLA), 1 also known as Bruton's disease, is a rare immunoglobulin deficiency characterized by severe decrease or absence of mature B cells and serum immunoglobulins (23) . Mutations in the Bruton's tyrosine kinase (Btk) gene have been shown to be responsible for a blockage at the preB stage (24, 25) , resulting in the accumulation of proB (CD34 (26) . The preB cells express normal amounts of -like and VpreB transcripts and a V-D-J-C repertoire characteristic of normal preB cells (26) . Conley and Sweinberg have reported in two girls a recessive disorder that is phenotypically identical to XLA but which is of possible autosomal origin (27) . Recently in a similar case, defect in the Btk gene was also ruled out (28) . In this patient, presence of CD10 ϩ cells but absence of CD19 ϩ cells and a 10-fold decrease of mature V-D-J-C transcripts suggested a blockage at an earlier stage of B cell development.
In this paper, we describe another young female patient with a severe agammaglobulinemia and demonstrate, by a detailed analysis of B cell subpopulations and B cell specific transcripts, a blockage at an early proB cell stage of the B cell differentiation pathway before the onset of Ig gene rearrangement. This case is reminiscent of the Pax5 Ϫ / Ϫ phenotype in the mouse (29) .
Methods
Case report. The patient is a girl born to healthy first cousin parents. From the age of 4 mo, she suffered from recurrent infections, consisting of otitis media, candidiasis, arthritis caused by Hemophilius influenzae , and Herpes simplex stomatitis associated with failure to thrive. She was referred to Hôpital des Enfants-Malades at the age of 11 mo for suspicion of an immunodeficiency condition. Lymphocyte counts were within normal range or increased (4,000-13,000/ l) while a neutropenia was detected (500/ l). In peripheral blood no serum immunoglobulins were detectable (IgG Ͻ 0.07 grams/liter, IgA Ͻ 0.08 grams/liter, IgM Ͻ 0.07 grams/liter). Lymphocyte phenotyping showed the absence of sIgM ϩ CD19 ϩ mature B cells, while T lymphocyte subsets were present (Table I) . The CD4 to CD8 ratio that was inverted in the first analysis (presumably due to an infectious episode) was normal as shown when rechecked 6 mo later. Mitogen-and antigeninduced proliferation was also found to be normal (Table I) . Cytogenetic analysis of lymphocytes did not detect any anomaly. In particular, a normal 46XX karyotype was observed both in blood and bone marrow of the patient (data not shown), excluding the possibility of a Turner syndrome or an X-autosome translocation. Furthermore, absence of detectable X-allelic polymorphism in this patient prevented X inactivation pattern analysis. After onset of intravenous immunoglobulin substitution, clinical status improved, growth normalized, and neutropenia resolved.
The parents gave informed consent for this study. The bone marrow sample was obtained when the patient was 18 mo old and under general anesthesia required for central line insertion. Age-matched control cells were an aliquot obtained from a healthy donor in the course of a bone marrow transplantation.
X inactivation pattern analysis. X inactivation pattern analysis was performed using a PCR-based detection of the X-linked androgen receptor gene as previously described (30), on DNA isolated from CD19
Ϫ and CD19 ϩ sorted cells from the patient's mother using a FACStar ® cell sorter (Becton Dickinson, San Diego, CA). Antibodies. Cell surface phenotyping was performed by direct immunofluorescence using FITC-mAb anti-CD10, anti-CD13, anti-CD19, anti-CD20, anti-CD22, anti-CD34, anti-CD38, or PE-mAb anti-␣ / ␤ TcR (BMA031, IgG1) or anti-␥ / ␦ TcR (IMMU510, IgG1) all purchased from Immunotech SA (Marseille, France). FITC-anti-CD3 (Leu 4, IgG1), anti-CD2 (Leu 5b, IgG2a), anti-CD4 (Leu 3a, IgG1), and PE-anti-CD8 (Leu 2a, IgG1) were from Becton Dickinson. FITC-sIgM was from Nordic Immunology (Tilburg, The Netherlands) and FITC-anti-CD24 was from Tebu Caltag Laboratories (San Francisco, CA). Indirect immunofluorescence using 9C2 (14) and 3C7 (22) anti-VpreB mAbs, and PE-labeled F(ab Ј ) 2 goat anti-mouse IgM (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) as revealing antibodies.
Cell surface staining. Cells (2 ϫ 10 5 ) were incubated with mAb for 30 min on ice. After three washes with PBS 0.2% BSA, 0.1% NaN 3 , cells were incubated for 30 min with 100 l of revealing antibodies. Irrelevant IgM mAb (IgM negative control; Immunotech SA) was included as a control. Immunofluorescence was analyzed using a FACScan ® analyzer (Becton Dickinson). Proliferation assays. PBMC were isolated from freshly drawn heparinized blood by means of Ficoll-Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden) density gradient centrifugation. Proliferation assays were performed as described elsewhere (31) . In brief, PBMC were stimulated either with 50 ng/ml of anti-CD3 ( PCR. cDNA from bone marrow cells was first prepared from total RNA of 4 ϫ 10 6 cells, using 150 ng of oligo dN6 as primer and the reverse transcriptase (BRL, Cergy-Pontoise, France), according to the manufacturer's instructions. PCR was performed in a Cetus apparatus using 1/20 of cDNA with 50 pmol of each oligonucleotide as primer (Table II) . To ensure that PCR products were not derived from DNA, primers were defined from discrete exons for each transcript, except Rag-1 and Rag-2. In these cases, RNA preparations were treated with DNase (Boehringer Mannheim Corp., Indianapolis, IN) and a PCR control without RT was included. Quantification was performed by reference to amplification of 25, 2.5, and 0.25 ng actin mRNA. The first cycle was run as follows: denaturation at 94 Њ C for 3 min, annealing at temperatures indicated in Table II for 1 min, and synthesis at 72 Њ C for 2 min. The next 28 cycles were run similarly, except that denaturation lasted only 1 min. For the last cycle, synthesis time was 7 min. One-fourth of the amplified products was run in agarose gel made 1 or 2% in 1 ϫ TBE.
Cloning and sequence analysis of the Pax-5 cDNA. PCR product of Pax-5 cDNA (1,208 bp) derived from patient bone marrow mononuclear cells was purified using QIA quick spin PCR purification kit (Qiagen, Coger, France) and cloned in competent Escherichia coli by using the TA cloning™ system (Invitrogen, Leek, The Netherlands). Double-strand DNA sequence of the PCR product was performed using the dideoxy chain termination protocol with 35 SdATP, a modified T7 DNA polymerase, a Sequenase kit (United States Biochemical Corp., Cleveland, OH), using Ϫ 40 and SP6 oligonucleotides and the following internal specific primers derived from the Pax-5 cDNA published sequence ( 
Results
Random X inactivation pattern of the patient's mother. Using a PCR-based detection of the X-linked androgen receptor gene (30) , a similar random X inactivation pattern was observed in the patient's mother for both the CD19 ϩ and CD19 Ϫ sorted PBMC, indicating that she was not an XLA carrier (data not shown). 
Phenotypic analysis of patient bone marrow cells reveals a major defect in B cell differentiation.
The main characteristic of the patient's PBMC was the absence of CD19 ϩ and surface ϩ cells (Table I) . For a more precise focus of the B cell impairment, bone marrow mononuclear cells were screened for a number of surface markers and compared with age-matched control, as indicated in Table III . CD34 expression was within normal values, whereas that of CD19, CD20, CD22, CD24, and surface ϩ which clearly assign commitment to the B lineage were severely depressed. Expression of CD10, although markedly diminished points to a defect which should be located at early B cell precursor stages. As shown earlier, 3C7 mAb iden- ) whereas 9C2 mAb also encompasses identification of preB stages (22) . Identification of surrogate light chain (⌿L) by both reagents therefore indicates that the B differentiation pathways proceeds at least to the proB stage.
Two-color FACS ® analysis performed on lymphoid cell gated populations visualized the absence of immature and/or mature B cells in patient's bone marrow (absence of and CD20, Fig. 1 B) . The CD34 Ϫ
CD19
ϩ preB cell population was also absent (Fig. 1 B) , and the CD34 ϩ
ϩ proB cell population decreased (1.6 vs. 8.6%). The few CD19 ϩ cells were positive for CD10 (2.5%, Fig. 1 A) and were mostly CD34 ϩ , strongly suggesting that differentiation did not proceed beyond proB cells. Presence of proB cells within the CD34 ϩ
CD10
ϩ population was also supported by the identification of ⌿L chain at the surface of 1.7% of CD34 ϩ cells. The CD34 ϩ CD10 ϩ was however smaller than that of the control (3.5 vs. 11%), indicating that the early proB compartment was already affected.
Identification of transcriptional defects in patient bone marrow cells. To approach the molecular defect, characterization of transcripts present in patient's cells was performed by RT-PCR using the primers described in Table II . Transcripts of total bone marrow cells from patient and age matched control were compared by reference to actin calibration (Fig. 2 A) . We chose to analyze transcripts directly linked to Ig gene expression or rear- (36) and Syk (37) , involved at a slightly later stage of differentiation, was also performed.
Among the classical markers directly linked to Ig gene expression, -like, VpreB, Rag-1, Rag-2, and TdT transcripts were clearly present in the same amount between the 2 samples (Fig. 2 B) . Pertaining to this group of nonaffected transcripts were also found Id, IL7R␣, and Btk (Fig. 2 B) . By contrast, expression of transcripts corresponding to the heavy (V-D-J-C) and light (V-C) Ig rearranged gene loci was highly impaired or absent, respectively (Fig. 2 C) . I (38) and I (39) sterile transcripts that initiate 5Ј of the E and E intronic enhancers, respectively, and which are normally expressed before the corresponding Ig gene rearrangements, were only faintly visible, as was the 0 sterile transcript that initiates 5Ј of the J H locus (40) , but it should be emphasized that in the control it was already rather weak. Finally, E2A, CD10, Syk, Pax-5, CD19, Ig␣, and Ig␤ expression was also affected in the patient, although at variable levels (Fig. 2 C) . A more precise evaluation of the affected transcripts could not be given due to the limits of the quantification technique.
Taken together these results are in agreement with the above FACS ® analysis, pointing to a blockage of differentiation at the proB stage in this patient, before the heavy chain locus rearrangements are completed.
Sequence determination of the Pax-5 cDNA. Because Pax-5 might be a potential candidate accounting for the observed defect (see below), PCR product encompassing the entire coding region (1,218 bp) was cloned and sequenced, using two external and three internal primers as indicated in Methods. Three independent clones failed to reveal any difference with the Pax-5 coding region previously reported (32).
Discussion
In this paper, we report the case of a young girl suffering a complete agammaglobulinemia with total absence of peripheral B cells, and normal T and myeloid compartments, thus resembling the phenotypic pattern of XLA. However, this syndrome may be eliminated for several reasons: (a) the patient is a girl born to first cousin healthy parents; (b) a normal 46XX karyotype was observed both in the blood and bone marrow of the patient, excluding the possibility of a Turner syndrome or an X-autosome translocation; and (c) the patient's mother was not an XLA carrier and therefore this case cannot result from Table I . A control without cDNA was included in the left column of each series (Ϫ). a maternal carrier associated to a spontaneous mutation from the father. Therefore, the origin of the disease may result rather from an homozygous defect of an autosomal gene. Although similar non-XLA primary immune deficiencies have been reported (27, 28, 41) , the precise stage of differentiation that was affected by the genetic defect was not characterized.
Systematic analysis of most classical markers of the B cell lineage in the patient's bone marrow indicates that this deficiency is the consequence of a block of differentiation at an early stage of B cell development first evidenced from the absence of surface and the quasi-absence of CD19, CD20, CD22, and CD24, leading to the lack of immature B cells. In humans, preB cells may be characterized by either the presence at their surface of the -⌿L complex (16, 17) or by the presence of intracytoplasmic chains in a CD34 
CD10
ϩ and essentially CD34
ϩ is consistent with the presence of a proB cell population, a conclusion which is strengthened by the fact that these cells expressed ⌿L epitopes in the absence of chains at their surface. However, this proB cell population is diminished, indicating a blockage within this compartment, i.e., earlier than the X-linked Btk defect characterized by the presence of both CD34 ϩ
CD19
ϩ proB cells and CD34 Ϫ CD19 ϩ preB cells (26, 42 ).
In the mouse, gene targeting has shed light on the sequential events that drive the early steps of B cell differentiation. Most of these genes encode transcription factors which control regulatory points that are critical in early stages of lymphopoiesis. They can be ordered as indicated in Fig. 3 , altogether with the kinetics of expression of the major transcripts that are involved in the differentiation of the B lineage. When searching for a gene that could account for the reported defect, one obvious track is to identify impairments of transcription. However, one should realize that several difficulties must be faced. First, extrapolation of results derived from gene targeting in the mouse to human situation may require some caution. For instance, clear differences have been identified between phenotypes of human XLA and Btk gene targeting (23, 26, (42) (43) (44) . Second, it may be difficult to decide whether the very low level of any one transcript is directly linked to the corresponding gene defect or whether it is diminished because of the lack of subsequent stages of differentiation. As appreciated from semiquantitative RT-PCR, two levels of transcript expression pattern could be identified (Fig. 2) . In the first one, composed of -like, VpreB, Rag-1, Rag-2, TdT, Id, IL7R␣, and Btk transcription level was identical to that of normal age-matched control indicating that the steps leading to the early proB were normal. Btk deserves a special comment in that it is also found expressed in the myeloid lineage (36) , which thus might contribute to the level of transcription observed in this patient. Absence or very low efficiency of Ig gene rearrangements was not due to an alteration of Rag-1 nor Rag-2, since the T compartment was normal. Nevertheless, a mutation that would affect the control of Rag transcription solely in the B lineage could be invoked, as this was reported to be the case for the E2A Ϫ/Ϫ phenotype (33) . In the second group, which included E2A, CD10, Syk, Pax-5, CD19, Ig␣, Ig␤, 0 , I, V H -C , I , and V -C , gene expression was severely impaired. As expression of these genes extends beyond the preB stage, the lower level of transcripts is most simply explained by the absence of more mature cells. The precise step of differentiation which is directly affected by the defect must be very close to the onset of transcription of these genes. In this regard, several genes must be critically analyzed. The presence of -like, VpreB, Rag-1 and Rag-2 transcripts in the patient rules out E2A defect, which was shown to severely impair transcription of these genes in the mouse (33) . The phenotype that results from gene targeting of Ig␤ is close to that of the patient in that blockage arises at the proB stage. However, its implication appears unlikely in our case, since in Ig␤ Ϫ/Ϫ mice V H -D-J H occurs, although with a low efficiency, and the level of Ig␣ transcription remains normal (45). Gene targeting of CD19 did not affect B cell differentiation until the immature B lymphocyte stage (46) , making it unlikely a direct defect of this gene in the patient. Among factors that control CD19 expression, Pax-5 transcription factor has been shown to be clearly involved (47) . Binding sites for Pax-5 have been also identified in the promoters of other B specific genes such as -like/5, VpreB, Blk, and at multiple sites within the IgH locus (48) . The very low level of CD19 transcription, the strong impairment in Ig gene rearrangements, and the presence of normal levels of -like and VpreB transcripts were reminiscent of the phenotype reported in Pax-5 Ϫ/Ϫ mice (29, 49) and therefore made the Pax-5 gene the most likely candidate to date (Fig. 3) . However, sequencing of the coding portion of the cDNA did not differ from the previously reported sequence, thus leaving the definitive answer with a question mark. Using a molecular genetic approach of primary immune deficiencies that may be similar to our case, Vorechovsky et al. concluded that involvement of the coding portion of the Pax-5 gene was unlikely (41) . However, implication of Pax-5 cannot be definitively ruled out, either directly through a mutation in the regulatory boxes of this gene, or by a defect of a gene encoding a factor regulating the Pax-5 gene. It should be recalled that Pax-5 also drives important steps of development in the posterior midbrain and anterior cerebellum in the mouse (29) . The patient had no evidence of such a syndrome, but this might be explained by the redundancy in the Pax gene family, Pax-2 being expressed in the central nervous system (50) .
Therefore, this new non-XLA primary immunodeficiency provides a potential model to attempt elucidation of very early stages of human B cell differentiation.
